Matches in Wikidata for { <http://www.wikidata.org/entity/Q70821781> ?p ?o ?g. }
Showing items 1 to 48 of
48
with 100 items per page.
- Q70821781 description "1983 թվականի հունվարի 1-ին հրատարակված գիտական հոդված" @default.
- Q70821781 description "article scientifique publié en 1983" @default.
- Q70821781 description "articolo scientifico (pubblicato il 1983)" @default.
- Q70821781 description "artigo científico (publicado na 1983)" @default.
- Q70821781 description "artikull shkencor i botuar më 01 janar 1983" @default.
- Q70821781 description "artículu científicu espublizáu en 1983" @default.
- Q70821781 description "im Jahr 1983 veröffentlichter wissenschaftlicher Artikel" @default.
- Q70821781 description "scientific article published on 01 January 1983" @default.
- Q70821781 description "wetenschappelijk artikel" @default.
- Q70821781 description "наукова стаття, опублікована в січні 1983" @default.
- Q70821781 name "[Therapy in metastasizing ovarian cancer--survival rate correlated with histological and cytological grading as prognostic factors]" @default.
- Q70821781 name "[Therapy in metastasizing ovarian cancer--survival rate correlated with histological and cytological grading as prognostic factors]" @default.
- Q70821781 name "[Therapy in metastasizing ovarian cancer--survival rate correlated with histological and cytological grading as prognostic factors]" @default.
- Q70821781 type Item @default.
- Q70821781 label "[Therapy in metastasizing ovarian cancer--survival rate correlated with histological and cytological grading as prognostic factors]" @default.
- Q70821781 label "[Therapy in metastasizing ovarian cancer--survival rate correlated with histological and cytological grading as prognostic factors]" @default.
- Q70821781 label "[Therapy in metastasizing ovarian cancer--survival rate correlated with histological and cytological grading as prognostic factors]" @default.
- Q70821781 prefLabel "[Therapy in metastasizing ovarian cancer--survival rate correlated with histological and cytological grading as prognostic factors]" @default.
- Q70821781 prefLabel "[Therapy in metastasizing ovarian cancer--survival rate correlated with histological and cytological grading as prognostic factors]" @default.
- Q70821781 prefLabel "[Therapy in metastasizing ovarian cancer--survival rate correlated with histological and cytological grading as prognostic factors]" @default.
- Q70821781 P1433 Q70821781-058FFA41-A6AD-405F-A9AB-880E3941C850 @default.
- Q70821781 P1476 Q70821781-25394398-334A-478F-AA63-D481FB002645 @default.
- Q70821781 P2093 Q70821781-35E4CD8D-CD5D-47F7-9EC1-42D10B924BEC @default.
- Q70821781 P2093 Q70821781-644E99A1-E4C9-4472-B5EC-3625F040F807 @default.
- Q70821781 P2093 Q70821781-DCF0EFA0-4CC3-4BE1-B09E-25D2A52F2BE8 @default.
- Q70821781 P2093 Q70821781-DE0BB1E3-0ABA-45CB-B9DF-A47BD28F23F4 @default.
- Q70821781 P304 Q70821781-360F1B6F-82B1-4E40-A961-1850B25C8AAC @default.
- Q70821781 P31 Q70821781-47A1F9B9-C29F-4F64-9231-375FDD962D0C @default.
- Q70821781 P356 Q70821781-C1272530-81FA-4B5C-98AD-51BE09E2B67F @default.
- Q70821781 P433 Q70821781-BFD40439-3831-4EEA-9FA6-686512641457 @default.
- Q70821781 P478 Q70821781-52D618CB-1009-417B-A73D-F00623FBE3BE @default.
- Q70821781 P577 Q70821781-9868F2B0-746F-41F4-BFB7-62848057FE55 @default.
- Q70821781 P698 Q70821781-9D4B0B05-E859-4E0B-9321-7C1D5DDB91FD @default.
- Q70821781 P356 S-2008-1037050 @default.
- Q70821781 P698 6550541 @default.
- Q70821781 P1433 Q26841999 @default.
- Q70821781 P1476 "[Therapy in metastasizing ovarian cancer--survival rate correlated with histological and cytological grading as prognostic factors]" @default.
- Q70821781 P2093 "Heberling D" @default.
- Q70821781 P2093 "Hoeffken H" @default.
- Q70821781 P2093 "Kaufmann M" @default.
- Q70821781 P2093 "Märkel S" @default.
- Q70821781 P304 "15-17" @default.
- Q70821781 P31 Q13442814 @default.
- Q70821781 P356 "10.1055/S-2008-1037050" @default.
- Q70821781 P433 "1" @default.
- Q70821781 P478 "43" @default.
- Q70821781 P577 "1983-01-01T00:00:00Z" @default.
- Q70821781 P698 "6550541" @default.